| abstract |
The present disclosure relates to anti-human CD154 antibodies with modified effector functions. The present disclosure also relates to the use of these anti-human CD154 antibodies in the treatment of conditions associated with CD154 activation, such as transplant rejection, inflammatory conditions and diseases, associated with viral infections and diseases Dysfunctional immune responses, autoimmune conditions and diseases, allergic conditions, atherosclerotic conditions or neurodegenerative conditions and diseases. The present disclosure also relates to the use of these anti-human CD154 antibodies to induce central tolerance and hematopoietic chimerism in transplant patients. |